SynthesisAntonie van Leeuwenhoek2026
The role of natural products in treatment of non-tuberculous mycobacterial infections: a systematic review.
Synthesis in Antonie van Leeuwenhoek, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the recent decades, Non-tuberculous mycobacteria (NTM) have posed an emerging clinical threat. The treatment of NTM infection poses therapeutic challenges owing to factors like drug-resistance of pathogens, presence of biofilms, and the time-consuming treatment regimens. Given high toxicity and limited efficacy of numerous established therapeutic agents, natural products have been explored extensively as alternative or adjuvant therapy for NTM. This systematic review focused on therapeutic benefits of natural products in NTM infection. Major biomedical literature databases (PubMed, Scopus, Web of Science, Embase, Cochrane Library, Google Scholar) were searched for publications till December 2025 to collect relevant articles detailing the impact of natural products on NTM organisms. We included in vitro studies, in vivo studies (animal models) and clinical trials that assessed the antimycobacterial actions of diverse natural product types. The quality and risk of bias have been appraised utilizing standard tools like ToxRTool and SYRCLE to evaluate the methodological rigor of the selected articles. Total of 19 studies were selected, the majority of which (n = 15) were laboratory-based. A variety of agents such as essential oils, isolated phytochemicals, and probiotics showed antimycobacterial activities targeting different NTM species such as M. avium and M. abscessus complexes. Several compounds such as Juniperus communis essential oil, Helichrysum italicum essential oil, berberine combinations, and citrus oil fractions, demonstrated significant activity when combined with conventional antimycobacterial agents or through the disruption of biofilm formation. Animal and clinical studies revealed less conclusive benefits, while few showed improved immunity or stable imaging, and substantial reduction in bacterial load was rarely achieved. Overall, the quality of current research is inconsistent, and further rigorous validation is needed. Although natural products show promise as antimycobacterial agents and their adjunctive actions in vitro, their clinical success remains limited and significant improvement is expected. Future rigorously planned experimental and clinical studies will need to validate the therapeutic role of these promising products in NTM management.
Indexed as
Identifiers
42680847What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.